Table 2 Characteristics of heart failure with preserved ejection fraction cohort
|  | HFpEF Cohort N = 80,248 |
|---|---|
Demographics | |
Age (years) | 72.5 (11.3) |
Male (%) | 96.5 |
Black or African American (%) | 12.3 |
Body mass index (kg/m2) (%) | Â |
 Underweight (<  18.5) | 1.5 |
 Normal (18.5–24.9) | 17.4 |
 Overweight (25.0–29.9) | 27.0 |
 Obese (30.0–34.9) | 23.7 |
 Morbidly obese (≥ 35.0) | 30.3 |
Clinical parameters | |
Heart rate (beats per minute) | 76.2 (16.0) |
Systolic blood pressure (mmHg) | 137.9 (23.4) |
Diastolic blood pressure (mmHg) | 73.0 (13.2) |
Mean LVEF (%) | 59.9 (5.9) |
Laboratory parameters | |
Serum sodium unit (mmol/L) | 138.8 (3.7) |
Hemoglobin (gm/dL) | 12.4 (2.2) |
BNP (pg/mL) | 313.5 (252.2) |
proBNP (pg/mL) | 397.4 (292.6) |
Serum creatinine (mg/dL) | 1.4 (1.0) |
eGFR (ml/min/1.73m2) | 60.7 (24.9) |
Serum potassium (mmol/L) | 4.2 (0.5) |
Serum BUN (mg/dL) | 23.3 (10.5) |
LDL cholesterol (mg/dL) | 89.5 (35.2) |
HDL cholesterol (mg/dL) | 40.6 (14.0) |
Triglycerides (mg/dL) | 143.4 (99.5) |
Total cholesterol (mg/dL) | 157.4 (45.1) |
Comorbidities | |
Atrial fibrillation (%) | 26.6 |
Stroke (%) | 6.2 |
Hypertension (%) | 88.4 |
Chronic liver disease (%) | 5.0 |
Chronic obstructive pulmonary disease (%) | 47.1 |
Chronic kidney disease (%) | 26.4 |
Diabetes (%) | 54.3 |
Hyperlipidemia (%) | 66.3 |
Peripheral vascular disease (%) | 27.6 |
Coronary artery disease (%) | 45.5 |
Sleep apnea (%) | 16.4 |
History of myocardial infarction (%) | 8.4S |
PCI/CABG (%) | 5.2 |
Medications | |
Angiotensin converting enzyme (%) | 52.2 |
Angiotensin receptor blocker (%) | 11.6 |
Beta blocker (%) | 59.5 |
Calcium channel blocker (%) | 40.3 |
Anticoagulants (%) | 15.4 |
Antiplatelets (%) | 11.6 |
Digoxin (%) | 9.0 |
Loop diuretics (%) | 69.9 |
Thiazide (%) | 16.2 |
Statins (%) | 53.9 |
Nitrates (%) | 16.2 |
Spironolactone (%) | 7.5 |